CHMP Meeting Update: Five New Medicines Recommended for Approval, Rejects Kisunla Application
CHMP recommends approval for five medicines, but rejects marketing authorization for Eli Lilly's Kisunla for early Alzheimer's disease. It also...
223 Views
Wuxi XDC Placement - Following Biologics Playbook, past Deals Have Been Mixed
WuXi AppTec (2359 HK) aims to raise around US$250m via selling around 3.5% stake in WuXi XDC Cayman (2268 HK). In this note, we talk about the deal...
347 Views
China Healthcare Weekly (Mar.2) - NewCo Model, Pfizer-Summit Deal, Henlius to Enter HK Stock Connect
The NewCo model is just an "intermediate state" for Chinese Biotech. After Pfizer-Summit deal, the possibility of Summit being acquired is reduced....
647 Views
Asia Real Estate Tracker (18-Feb-2025): ADIA, Hines sell Shanghai Trophy Tower for $1.5B
ADIA and Hines sell Shanghai Tower for $1.5B, Keppel DC REIT sells German data centre, TPG offers $65M for Econ Healthcare, while Singapore home...
258 Views
APAC Healthcare Weekly (Feb 16)- Hansoh Pharma, Astellas Pharma, CSL, Imugene, LigaChem Bio, Lupin
APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...
659 Views